These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 30244085)
61. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Yu L; Wang Z; Mo Z; Zou B; Yang Y; Sun R; Ma W; Yu M; Zhang S; Yu Z Acta Pharm Sin B; 2021 Jul; 11(7):2004-2015. PubMed ID: 34386334 [TBL] [Abstract][Full Text] [Related]
62. Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Li CJ; Chu CY; Huang LH; Wang MH; Sheu LF; Yeh JI; Hsu HY Cancer Lett; 2012 Jun; 319(2):203-213. PubMed ID: 22306340 [TBL] [Abstract][Full Text] [Related]
63. Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Kong LL; Zhuang XM; Yang HY; Yuan M; Xu L; Li H Sci Rep; 2015 Jul; 5():11747. PubMed ID: 26134275 [TBL] [Abstract][Full Text] [Related]
64. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells. Long C; Guo W; Zhou H; Wang J; Wang H; Sun X Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279 [TBL] [Abstract][Full Text] [Related]
65. [Preparation and toxicity of triptolide-loaded poly (D,L-lactic acid) nanoparticles]. Liu MX; Dong J; Yang YJ; Yang XL; Xu HB Yao Xue Xue Bao; 2004 Jul; 39(7):556-60. PubMed ID: 15493850 [TBL] [Abstract][Full Text] [Related]
66. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765 [TBL] [Abstract][Full Text] [Related]
67. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment. Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310 [TBL] [Abstract][Full Text] [Related]
68. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma. Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029 [TBL] [Abstract][Full Text] [Related]
69. ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells. Li F; Zhao D; Yang S; Wang J; Liu Q; Jin X; Wang W Cell Physiol Biochem; 2018; 45(3):917-934. PubMed ID: 29428961 [TBL] [Abstract][Full Text] [Related]
70. Synthesis, characterization and in vitro evaluation of triptolide-lysozyme conjugate for renal targeting delivery of triptolide. Zheng Q; Gong T; Sun X; Zhang ZR Arch Pharm Res; 2006 Dec; 29(12):1164-70. PubMed ID: 17225468 [TBL] [Abstract][Full Text] [Related]
71. Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice. Varshney A; Panda JJ; Singh AK; Yadav N; Bihari C; Biswas S; Sarin SK; Chauhan VS Hepatology; 2018 Apr; 67(4):1392-1407. PubMed ID: 29108133 [TBL] [Abstract][Full Text] [Related]
72. Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma. Xue WJ; Feng Y; Wang F; Guo YB; Li P; Wang L; Liu YF; Wang ZW; Yang YM; Mao QS Sci Rep; 2016 Feb; 6():22149. PubMed ID: 26915683 [TBL] [Abstract][Full Text] [Related]
73. In vivo evaluation of the safety of triptolide-loaded hydrogel-thickened microemulsion. Xu L; Pan J; Chen Q; Yu Q; Chen H; Xu H; Qiu Y; Yang X Food Chem Toxicol; 2008 Dec; 46(12):3792-9. PubMed ID: 18952137 [TBL] [Abstract][Full Text] [Related]
74. Kinetic release of triptolide after injection of renal-targeting 14-succinyl triptolide-lysozyme in a rat kidney study by liquid chromatography/mass spectrometry. Zheng Q; Ye L; Gao R; Han J; Xiong M; Zhao D; Gong T; Zhang Z Biomed Chromatogr; 2007 Jul; 21(7):724-9. PubMed ID: 17370252 [TBL] [Abstract][Full Text] [Related]
75. Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-ɑ siRNA provide a novel strategy for the experimental treatment of ulcerative colitis. Huang Y; Guo J; Gui S Eur J Pharm Sci; 2018 Dec; 125():232-243. PubMed ID: 30315858 [TBL] [Abstract][Full Text] [Related]
76. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180. Lin Y; Yang X; Lu M; Zheng W; Zhang J; Zhuang H; Hua ZC Anticancer Drugs; 2013 Oct; 24(9):945-57. PubMed ID: 23958791 [TBL] [Abstract][Full Text] [Related]
77. Metabolic pathways leading to detoxification of triptolide, a major active component of the herbal medicine Tripterygium wilfordii. Du F; Liu Z; Li X; Xing J J Appl Toxicol; 2014 Aug; 34(8):878-84. PubMed ID: 23836259 [TBL] [Abstract][Full Text] [Related]
78. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219 [TBL] [Abstract][Full Text] [Related]
79. Integrated targeted sphingolipidomics and transcriptomics reveal abnormal sphingolipid metabolism as a novel mechanism of the hepatotoxicity and nephrotoxicity of triptolide. Qu L; Qu F; Jia Z; Wang C; Wu C; Zhang J J Ethnopharmacol; 2015 Jul; 170():28-38. PubMed ID: 25978956 [TBL] [Abstract][Full Text] [Related]
80. Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin. Yuan ZX; Wu XJ; Mo J; Wang YL; Xu CQ; Lim LY Eur J Pharm Biopharm; 2015 Aug; 94():363-71. PubMed ID: 26117184 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]